- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03763032
Psychosocial Intervention in Latino Patients With Advanced Cancer
September 11, 2023 updated by: University of Colorado, Denver
Expanding the Reach of Palliative Care: Pilot Study of a Psychosocial Intervention in Latino Patients With Advanced Cancer
Palliative Care focuses on symptom management and quality of life and helps patients with life-limiting illness match goals and preferences for care.
While there has been interest in and acknowledgement that palliative care is an important part of training patient navigators, there have been no previous studies examining the effectiveness of a navigation intervention to improve palliative care for patients.
This study will examine the feasibility to implement patient navigator and psychosocial interventions.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80218
- University of Colorado
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults ages > or = 18 years of age
- Must self-identify as Latino/a
- Have stage III/IV cancer
- Seeking or In treatment for their cancer (ie: not in hospice care)
- Not incarcerated
- Have at least moderate baseline distress (> 4 on the NCCN Distress Thermometer) or positive screen for depression (PHQ-2 score >=3) or anxiety (GAD-2 score >=3)
Exclusion Criteria:
-No exclusion criteria listed
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stepped Interventions
Patient navigation intervention, plus various psychosocial interventions
|
The patient navigator will provide educational materials, assessments, and counseling to the patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of Recruitment: number of patients that are eligible to participate
Time Frame: Start of study to end of study, up to 12 months
|
Assess how likely patients are to join the study through tracking the number of patients that are eligible to participate.
|
Start of study to end of study, up to 12 months
|
Feasibility of Completion: number of patients that complete the study
Time Frame: Start of study to end of study, up to 12 months
|
Assess how likely patients are to adhere to the study through tracking the number of patients that complete the study.
|
Start of study to end of study, up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Process Measure Assessment
Time Frame: Start of study to end of study, up to 12 months
|
Use the Advance Care Planning Engagement Survey to assess Behavior.
9 item questionnaire based on Change Theory using a 6 point Likert scale.
Total score is a mean of all items with a range of 1-6.
|
Start of study to end of study, up to 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FACT-G Quality of Life Assessment
Time Frame: Start of study to end of study, up to 12 months
|
Assess each patient's quality of life through the Function Assessment of Chronic Illness Therapy-General (FACT-G), which is a 27 question self-reporting measure of quality of life.
Scale range is 0-108, higher scores indicating higher quality of life.
|
Start of study to end of study, up to 12 months
|
Depression Assessment
Time Frame: Start of study to end of study, up to 12 months
|
Use the Patient Health Questionnaire-8 to measure depressive symptoms through an 8 item assessment.
Score ranges are 0-24, higher scores representing more depressive symptoms.
|
Start of study to end of study, up to 12 months
|
Anxiety Assessment
Time Frame: Start of study to end of study, up to 12 months
|
Use the Generalize Anxiety Disorder-7 to measure symptoms of anxiety through a 7 question assessment.
Score range is 0-21, with increased scores representing higher levels of anxiety.
|
Start of study to end of study, up to 12 months
|
Pain Assessment: PEG questionnaire
Time Frame: Start of study to end of study, up to 12 months
|
The PEG questionnaire assesses pain intensity and interference on a numeric rating scale.
Scale range of each of three items is 0-10.
Total score is the mean of the three item scores.
|
Start of study to end of study, up to 12 months
|
Symptom Severity Assessment
Time Frame: Start of study to end of study, up to 12 months
|
Use the Edmonton Symptom Assessment Scale (ESAS-r) to assess symptom severity on a numeric rating scale.
Score range for each of the 9 items is 0-10 with total score summary of all individual symptom items.
|
Start of study to end of study, up to 12 months
|
Hospital Assessments
Time Frame: Start of study to end of study, up to 12 months
|
Evaluate the frequency of hospitalizations or deaths through patient medical records
|
Start of study to end of study, up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stacy Fischer, MD, University of Colorado, Denver
- Principal Investigator: David Bekelman, MD, University of Colorado, Denver
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 23, 2018
Primary Completion (Actual)
July 31, 2018
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
November 30, 2018
First Submitted That Met QC Criteria
December 3, 2018
First Posted (Actual)
December 4, 2018
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 11, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-1955.cc
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
Bristol-Myers SquibbRecruitingAdvanced CancerUnited States, Spain, Belgium, Argentina, Korea, Republic of, Japan
Clinical Trials on Counseling
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States
-
Texas Christian UniversityTerminated
-
Port Said UniversityMansoura University; Prince Sattam Bin Abdulaziz UniversityRecruitingFertility IssuesEgypt
-
Loyola UniversityCompletedUterine Leiomyoma
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiCompletedAnxiety | Knowledge, Attitudes, Practice | Decision Making | Chromosome AbnormalityTurkey
-
University of PadovaFondazione Guido Berlucchi; Veneto Institute of Oncology I.O.V.-I.R.C.C.S.Terminated
-
International Centre for Diarrhoeal Disease Research...Completed
-
David A KatzAmerican Heart AssociationCompleted
-
Lata Medical Research Foundation, NagpurUnknownMalnutrition in Pregnancy | Other Disorders of Breast and Lactation Associated With ChildbirthIndia
-
University of PennsylvaniaCompletedPolycystic Ovary Syndrome (PCOS)United States